TrueWealth LLC’s Novartis NVS Stock Holding History

TrueWealth LLC’s Portfolio NVS Stock Details NVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	$33K	Sell	373 -99	-21%	-$8.55K	0.01%	319
2020 Q1	$39K	Sell	472 -250	-35%	-$22.3K	0.02%	278
2019 Q4	$68K	Hold	722	–	–	0.03%	238
2019 Q3	$63K	Hold	722	–	–	0.03%	241
2019 Q2	$66K	Sell	722 -84	-10%	-$7.11K	0.03%	236
2019 Q1	$69K	Hold	806	–	–	0.03%	231
2018 Q4	$62K	Hold	806	–	–	0.03%	227
2018 Q3	$62K	Buy	806 +35	+5%	+$2.59K	0.03%	245
2018 Q2	$52K	Hold	771	–	–	0.02%	262
2018 Q1	$56K	Hold	771	–	–	0.03%	248
2017 Q4	$58K	Buy	+771	New	+$58.2K	0.03%	269

Other funds holding NVS

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Mawer Investment Management Calgary, Alberta, Canada $15.4B AUM 10.9% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return

TrueWealth LLC's NVS Position: Q2 2020 in Review

TrueWealth LLC reduced its Novartis (NVS) stake by 21% in Q2 2020, selling an estimated $8.55K and leaving 373 shares worth $33K. The position accounts for 0.01% of the portfolio, ranked #319.

TrueWealth LLC first reported a position in NVS in Q4 2017 and has held it in 11 quarters since. The position peaked at $69K in Q1 2019. 1,129 funds tracked by Wall St. Rank hold NVS as of Q2 2020.

TrueWealth LLC held 373 shares of Novartis worth $33K as of Q2 2020.
TrueWealth LLC sold 99 Novartis shares in Q2 2020, an estimated $8.55K.
Novartis made up 0.01% of TrueWealth LLC's portfolio in Q2 2020, its #319 holding.
TrueWealth LLC first reported a position in Novartis in Q4 2017 and has held it in 11 quarters since.
TrueWealth LLC's Novartis position peaked at $69K in Q1 2019.
1,129 funds tracked by Wall St. Rank held Novartis as of Q2 2020.

Based on TrueWealth LLC's 13F filing for Q2 2020, filed 15 Jul 2020.